GDC-2394 is an orally active and selective
[1]. McBride C, et al. Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexadro-s-indacen-4-yl)carbamoyl)-6-(metlamino)-6,7-didro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor. J Med Chem. 2022 Oct 24.
[2]. Stafford, et al. Preparation of hexadroindacenylcarbamoyldidropyrazolooxazinesulfonamide derivatives and analogs for use as interleukin-1 activity inhibitors: World Intellectual Property Organization, WO2018136890[P]. 2018-07-26.
















